US5872154A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of reducing an immune response to a recombinant adenovirus
Assignee: University of Pennsylvania
•
Filing: 1995-02-24
•
Granted: 1999-02-16
•
Expires: 2015-02-24
Abstract
Abstract A method of reducing an immune response to a recombinant adenovirus which involves co-administration of the recombinant adenovirus and a selected immune modulator. The immune modulator functions by inhibiting the formation of neutralizing antibodies and/or reducing CTL killing of the virally infected cells. The method additionally encompasses the step of re-administering the recombinant adenovirus.
Inventors
- 👤 James M. Wilson
- 👤 Yiping Yang
- 👤 Giorgio Trinchieri
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 08:17
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; A; A61; A61K; A61K35/00; A61K35/66; A61K35/76; A61K35/761; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/20; A61K38/208; A61K38/21; A61K38/217; A61K39/00; A61K39/395; A61K48/00; C12N7/00; C12N2710/00; C12N2710/00011; C12N2710/10011; C12N2710/10311; C12N2710/10332; C12N2710/10341; C12N2710/10343
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
39 words
A method of inhibiting in a mammal formation of neutralizing antibodies directed against a recombinant adenovirus comprising the step of co-administering to said mammal said adenovirus and an antibody directed against CD4, wherein formation of neutralizing antibodies is inhibited.
Claim 2
Independent Claim
39 words
A method of inhibiting in a mammal formation of neutralizing antibodies directed against a recombinant adenovirus comprising the step of co-administering to said mammal said adenovirus and an antibody directed against CD4, wherein formation of neutralizing antibodies is inhibited.
Claim 3
Dependent Claim
14 words
The method according to claim 1, further comprising the step of re-administering the adenovirus.
Claim 4
Dependent Claim
15 words
The method according to claim 1, wherein CTL killing of virally infected cells is reduced.
Claim 5
Dependent Claim
18 words
The method according to claim 1, wherein said antibody directed against CD4 is administered simultaneously with said adenovirus.
Claim 6
Dependent Claim
20 words
The method according to claim 1, wherein said antibody directed against CD4 is administered prior to administration of said adenovirus.
Claim 7
Dependent Claim
20 words
The method according to claim 1, wherein said antibody directed against CD4 is administered subsequently to administration of said adenovirus.
Claim 8
Independent Claim
35 words
A method of inhibiting in a mammal formation of neutralizing antibodies directed against a recombinant adenovirus comprising the step of co-administering to said mammal said adenovirus and interleukin-12, wherein formation of neutralizing antibodies is inhibited.
Claim 9
Independent Claim
35 words
A method of inhibiting in a mammal formation of neutralizing antibodies directed against a recombinant adenovirus comprising the step of co-administering to said mammal said adenovirus and interleukin-12, wherein formation of neutralizing antibodies is inhibited.
Claim 10
Dependent Claim
14 words
The method according to claim 7, further comprising the step of re-administering said adenovirus.
Claim 11
Dependent Claim
15 words
The method according to claim 7, wherein said interleukin-12 is administered simultaneously with said adenovirus.
Claim 12
Dependent Claim
17 words
The method according to claim 7, wherein said interleukin-12 is administered prior to administration of said adenovirus.
Claim 13
Dependent Claim
17 words
The method according to claim 7, wherein said interleukin-12 is administered subsequently to administration of said adenovirus.
Claim 14
Independent Claim
35 words
A method of inhibiting in a mammal formation of neutralizing antibodies directed against a recombinant adenovirus comprising the step of co-administering to said mammal said adenovirus and interferon-gamma, wherein formation of neutralizing antibodies is inhibited.
Claim 15
Independent Claim
35 words
A method of inhibiting in a mammal formation of neutralizing antibodies directed against a recombinant adenovirus comprising the step of co-administering to said mammal said adenovirus and interferon-gamma, wherein formation of neutralizing antibodies is inhibited.
Claim 16
Dependent Claim
14 words
The method according to claim 12, further comprising the step of re-administering said adenovirus.
Claim 17
Dependent Claim
15 words
The method according to claim 12, wherein said interferon-gamma is administered simultaneously with said adenovirus.
Claim 18
Dependent Claim
17 words
The method according to claim 12, wherein said interferon-gamma is administered prior to administration of said adenovirus.
Claim 19
Dependent Claim
17 words
The method according to claim 12, wherein said interferon-gamma is administered subsequently to administration of said adenovirus.
Claim 20
Independent Claim
40 words
A method of inhibiting in a mammal formation of neutralizing antibodies directed against a recombinant adenovirus comprising the step of co-administering to said mammal said adenovirus and an antibody directed against CD40 ligand, wherein formation of neutralizing antibodies is inhibited.
Claim 21
Independent Claim
40 words
A method of inhibiting in a mammal formation of neutralizing antibodies directed against a recombinant adenovirus comprising the step of co-administering to said mammal said adenovirus and an antibody directed against CD40 ligand, wherein formation of neutralizing antibodies is inhibited.
Claim 22
Dependent Claim
14 words
The method according to claim 17, further comprising the step of re-administering said adenovirus.
Claim 23
Dependent Claim
19 words
The method according to claim 17, wherein said antibody directed against CD40 ligand is administered simultaneously with said adenovirus.
Claim 24
Dependent Claim
21 words
The method according to claim 17, wherein said antibody directed against CD40 ligand is administered prior to administration of said adenovirus.
Claim 25
Dependent Claim
21 words
The method according to claim 17, wherein said antibody directed against CD40 ligand is administered subsequently to administration of said adenovirus.
References Cited (Backward Citations)
US4658019A
Cited
US5017691A
Cited
US5166320A
Cited
WO1990005147A1
Cited
US5457038A
Cited
US5240846A
Cited
WO1991018088A1
Cited
EP0501233A1
Cited
US5290540A
Cited
WO1992019266A1
Cited
WO1993000431A1
Cited
EP0555880A2
Cited
WO1994012649A2
Cited
EP0609739A1
Cited
WO1994017832A1
Cited
US5419900A
Cited
WO1996012030A1
Cited
WO1996012406A1
Cited
WO1996014061A1
Cited
WO1996018418A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-02-15 | 2002-08-17 | 2003-02-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-02-15 | 2006-08-17 | 2007-02-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-02-15 | 2010-08-17 | 2011-02-16 | $7700.00 | Window Closed / Lapsed |